EN DE
Data-driven stock valuation

Sunny Pharmtech Inc. (6676) fair value: what the stock is really worth

We calculate from audited financials what Sunny Pharmtech Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · TW · Market cap 2.2B TWD (≈ $69.9M) · ISIN TW0006676000

At a glance

SP Sunny Pharmtech Inc. 6676 · TWO
Price12.00 TWD
Fair Value3.89 TWD
Upside−67.6%
Quality32/100

Below-average quality, and trading another 208% above our fair value of 3.89 TWD.

As of Aug 22, 2026, the fair value of Sunny Pharmtech Inc. is 3.89 TWD per share against a price of 12.00 TWD, so the fair value sits 68% below the price. A model estimate from reported figures, not an analyst target.

!Mixed Growth (revenue 5y +12.3 %/yr)
!Loss-making · -119.4% net margin
!Low debt · negative free cash flow
!Trails peers (2/10)
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
Evidence: Low Range 2.90 TWD to 5.81 TWD

Fair value as of: Aug 22, 2026

From 1 valuation models · updated 19 days ago

Share price −1.6% over the past month.

Watch Sunny Pharmtech Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (5.81 TWD). The favourable scenario is already priced in.
  • Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range (2.90 TWD to 5.81 TWD) leaves room in how you read the outcome.

Price vs Fair Value (9 months)

18.50 TWD 11.45 TWD Fair Value 3.89 TWD Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Aug 22, 2026.

How to read this chart

9‑month range 11.45 TWD – 18.50 TWD · fair‑value band 2.90 TWD – 5.81 TWD · the 12.00 TWD price screens above the 3.89 TWD fair value. As of Aug 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Sunny Pharmtech Inc. (6676) currently trades at 12.00 TWD, while our model-based Fair Value estimate is 3.89 TWD, implying the stock looks roughly 208.5% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Trailing-twelve-month revenue stands at 253M TWD. Revenue declined 20.2% year over year. It earns a return on equity of −33.5%. Net debt stands at 248M TWD. Fundamentals as of Aug 22, 2026

Scenario range: 2.90 TWD (bear) to 5.81 TWD (bull), the price of 12.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 37% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −68%, 6676 screens richer than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) best evidence 3.08 TWD 4.13 TWD 6.17 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) best evidence 3.08 TWD 4.13 TWD 6.17 TWD 54

Notify me when 6676 reaches fair value

Put 6676 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 8.68 TTM
EPS (TTM) −2.03 TWD
Net margin −37.3% FY2024
Return on equity −33.5% TTM
Return on assets (EBIT) −8.4% avg 5y
Operating margin −121% TTM
More key figures
Growth
Revenue (TTM) 253M TWD TTM
Revenue growth (YoY) −20.2% 3y avg +20.2%
Balance sheet & cash flow
Free cash flow −86.6M TWD FY2024
Net debt 248M TWD FY2024

Figures from reported company fundamentals · as of Aug 22, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 32/100

Of which business quality 33 · Market factors (momentum, volatility) 32

Profitability 7
Margins and returns on capital today
Quality Growth 13
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 71
Balance sheet, leverage, solvency risk
Investment 82
Disciplined investing over empire-building
Low Volatility 65
Calm price path (market factor)
Momentum 24
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 46
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally.

Full company description

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug in Taiwan, the United States, and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for blood diseases, as well as for hyper-proteolytic enzymes; and carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage, as well as Cyclophosphamide injection for malignant diseases. The company was founded in 2014 and is based in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Sunny Pharmtech Inc. reported revenue of 418M TWD in FY2024 versus 420M TWD in FY2020, a compound −0.1%/yr. Reported net income was −156M TWD in FY2024.

Growth Quality 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
418M TWD
Latest YoY
−2.5%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+20.2%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.3%
EBIT margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−91.3% (2019) → −39.0% (2024)
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed
Revenue −0.1%/yr
FY20 420M TWD
FY21 241M TWD
FY22 360M TWD
FY23 429M TWD
FY24 418M TWD
Net income
FY20 −102M TWD
FY21 −175M TWD
FY22 −170M TWD
FY23 −63.3M TWD
FY24 −156M TWD

6676 screens 208% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sunny Pharmtech Inc. · Fair Value
3.89 TWD −208%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sunny Pharmtech Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6676

Peer Group

Biotechnology · 633 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 33 · Below median
Fair Value upside −68% · Below median
Profitability
Return on assets −13% · Below median
Net margin (TTM) −119% · Bottom 25%
Operating margin (TTM) −121% · Bottom 25%
Growth and dividend
Revenue growth −20% · Bottom 25%
Balance sheet
Debt / equity 0.28× · Highest 25%

Valuation Multiples vs Biotechnology median · lower = cheaper

P/B 0.07× · Cheapest 25%
P/S (TTM) 0.27× · Cheapest 25%

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE0 · sector 0
PAST0 · sector 0
HEALTH86 · sector 98
DIVIDEND0 · sector 25

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 22, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,452,000 KRW 1,055,793 KRW −27%
CSL Limited CSL A$174.50 A$141.68 −19%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE 22UA €80.60 €52.92 −34%

Compare Sunny Pharmtech Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Sunny Pharmtech Inc. (6676) overvalued or undervalued?
As of Aug 22, 2026, our model estimates a fair value of 3.89 TWD versus a price of 12.00 TWD, about −68% upside (overvalued).
What is the fair value of 6676?
Our model-based fair value for Sunny Pharmtech Inc. is 3.89 TWD (as of Aug 22, 2026), built from audited fundamentals. The current price: 12.00 TWD.
What is the quality score of 6676?
Sunny Pharmtech Inc. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sunny Pharmtech Inc. (6676)?
Our model-based price target is the fair value of 3.89 TWD (as of Aug 22, 2026) from 1 valuation models. Cautious scenario 2.90 TWD, optimistic scenario 5.81 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Sunny Pharmtech Inc. stock forecast for 2026?
Our models put fair value at 3.89 TWD, about −68% upside versus a price of 12.00 TWD (overvalued). Cautious scenario 2.90 TWD, optimistic scenario 5.81 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Sunny Pharmtech Inc. (6676)?
Sunny Pharmtech Inc. reported trailing-twelve-month revenue of about 253M TWD (latest available figure, as of Aug 22, 2026).
What is the net profit margin of 6676?
The net profit margin of Sunny Pharmtech Inc. is about −119.4%, meaning it is currently running at a net loss. Based on the latest reported figures.
What is the intrinsic value of Sunny Pharmtech Inc. (6676)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sunny Pharmtech Inc. it is 3.89 TWD per share (as of Aug 22, 2026), against a price of 12.00 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sunny Pharmtech Inc. stock overvalued or undervalued in 2026?
As of Aug 22, 2026, 6676 trades above its calculated fair value: price 12.00 TWD, fair value 3.89 TWD, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6676?
No. The price is what the market pays today (12.00 TWD); the fair value is what the company's own numbers justify (3.89 TWD). For Sunny Pharmtech Inc. the two are 8.11 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Sunny Pharmtech Inc. worth?
The market values Sunny Pharmtech Inc. at about 2.2B TWD (market capitalisation, as of Aug 22, 2026). Per share that is 12.00 TWD; our models calculate a fair value of 3.89 TWD per share.
What do the bullish and bearish scenarios say about 6676?
Our models span a range for Sunny Pharmtech Inc.: cautious scenario 2.90 TWD, base 3.89 TWD, optimistic 5.81 TWD per share (as of Aug 22, 2026, price 12.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sunny Pharmtech Inc. (6676)?
Balance-sheet figures for Sunny Pharmtech Inc. (as of Aug 22, 2026): return on equity −33.5%, debt of 0.28 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 6676 from its 52-week high?
Sunny Pharmtech Inc. trades at 12.00 TWD, about 37% below its 52-week high of 19.10 TWD (as of Aug 22, 2026). Distance from the high says nothing about value: that is what the fair value of 3.89 TWD is for.
Which stocks are comparable to Sunny Pharmtech Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sunny Pharmtech Inc. stock attractive at the current price?
The data as of Aug 22, 2026: price 12.00 TWD, calculated fair value 3.89 TWD (−68%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6676 calculated?
We run Sunny Pharmtech Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.89 TWD, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed

Watch Sunny Pharmtech Inc. in the live analysis

One click puts Sunny Pharmtech Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.